HOME > 研究業績詳細

研究業績詳細

横溝 岳彦(ヨコミゾ タケヒコ)

研究テーマ 生理活性脂質受容体研究
研究業績(論文) 1. Takahashi N., T. Okuno, H. Fujii, S. Makino, M. Takahashi, M. Ohba, K. Saeki, A. Itakura, S. Takeda, T. Yokomizo. Up-regulation of cytosolic prostaglandin E synthase in fetal-membrane and amniotic prostaglandin E2 accumulation in labor. PLoS One 16, e0250638 (2021) (doi:10.1371/journal.pone.0250638)

2. Suchiva P., T. Takai, S. Kamijo, N. Maruyama, T. Yokomizo, Y. Sugimoto, K. Okumura, S. Ikeda, H. Ogawa. Inhibition of Both Cyclooxygenase-1 and -2 Promotes Epicutaneous Th2 and Th17 Sensitization and Allergic Airway Inflammation on Subsequent Airway Exposure to Protease Allergen in Mice. Int. Arch. Allergy Immunol. 1-12 (2021) (doi:10.1159/000514975)

3. Okuno T., T. Yokomizo. Metabolism and biological functions of 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid. Prostaglandins Other Lipid Mediat. 152, 106502 (2021) (doi:10.1016/j.prostaglandins.2020.106502)

4. Lee-Okada H.C., K. Hama, K. Yokoyama, T. Yokomizo. Development of a liquid chromatography-electrospray ionization tandem mass spectrometric method for the simultaneous analysis of free fatty acids. J. Biochem. (Tokyo). (2021) (doi:10.1093/jb/mvab054)

5. Jimbo K., T. Okuno, R. Ohgaki, K. Nishikubo, Y. Kitamura, Y. Sakurai, L. Quan, H. Shoji, Y. Kanai, T. Shimizu, T. Yokomizo. Correction: A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. PLoS One 16, e0247691 (2021) (doi:10.1371/journal.pone.0247691)

6. Hayashi Y., H.C. Lee-Okada, E. Nakamura, N. Tada, T. Yokomizo, Y. Fujiwara, I. Ichi. Ablation of fatty acid desaturase 2 (FADS2) exacerbates hepatic triacylglycerol and cholesterol accumulation in polyunsaturated fatty acid-depleted mice. FEBS Lett. (2021) (doi:10.1002/1873-3468.14134)

7. Hara T., K. Saeki, H. Jinnouchi, S. Kazuno, Y. Miura, T. Yokomizo. The c-terminal region of BLT2 restricts its localization to the lateral membrane in a LIN7C-dependent manner. FASEB J. 35, e21364 (2021) (doi:10.1096/fj.202002640R)

8. Yuki K., W. Bu, R.G. Eckenhoff, T. Yokomizo, T. Okuno. The role of propofol hydroxyl group in 5-lipoxygenase recognition. Biochem. Biophys. Res. Commun. 525, 909-914 (2020) (doi:10.1016/j.bbrc.2020.03.037)

9. Yasukawa K., T. Okuno, T. Yokomizo. Eicosanoids in Skin Wound Healing. Int J Mol Sci 21, 8435 (2020) (doi:10.3390/ijms21228435)

10. Uzawa H., D. Kohno, T. Koga, T. Sasaki, A. Fukunaka, T. Okuno, A. Jo-Watanabe, S. Kazuno, T. Miyatsuka, T. Kitamura, Y. Fujitani, H. Watada, K. Saeki, T. Yokomizo. Leukotriene A4 hydrolase deficiency protects mice from diet-induced obesity by increasing energy expenditure through neuroendocrine axis. FASEB J. 34, 13949-13958 (2020) (doi:10.1096/fj.202001148R)

11. Takahashi S.S., Y.S. Sou, T. Saito, A. Kuma, T. Yabe, Y. Sugiura, H.C. Lee, M. Suematsu, T. Yokomizo, M. Koike, S. Terai, N. Mizushima, S. Waguri, M. Komatsu. Loss of autophagy impairs physiological steatosis by accumulation of NCoR1. Life Sci Alliance 3, e201900513 (2020) (doi:10.26508/lsa.201900513)

12. Suzumura A., H. Kaneko, Y. Funahashi, K. Takayama, M. Nagaya, S. Ito, T. Okuno, T. Hirakata, N. Nonobe, K. Kataoka, H. Shimizu, R. Namba, K. Yamada, F. Ye, Y. Ozawa, T. Yokomizo, H. Terasaki. n-3 Fatty Acid and Its Metabolite 18-HEPE Ameliorate Retinal Neuronal Cell Dysfunction by Enhancing Muller BDNF in Diabetic Retinopathy. Diabetes 69, 724-735 (2020) (doi:10.2337/db19-0550)

13. Nakajima S., N. Ogawa, N. Yokoue, H. Tachibana, K. Tamada, M. Okazawa, A. Sato, T. Oyama, H. Abe, T. Kamiya, A. Yoshimori, K. Yoshizawa, S. Inoue, T. Yokomizo, F. Uchiumi, T. Abe, S.I. Tanuma. Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways. Biochem. Biophys. Res. Commun. 533, 1155-1161 (2020) (doi:10.1016/j.bbrc.2020.09.126)

14. Matsumoto Y., Y. Matsuya, K. Nagai, K. Amagase, K. Saeki, K. Matsumoto, T. Yokomizo, S. Kato. Leukotriene B4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation. J. Pharmacol. Exp. Ther. 373, 1-9 (2020) (doi:10.1124/jpet.119.263145)

15. Koga T., F. Sasaki, K. Saeki, S. Tsuchiya, T. Okuno, M. Ohba, T. Ichiki, S. Iwamoto, H. Uzawa, K. Kitajima, C. Meno, E. Nakamura, N. Tada, Y. Fukui, J. Kikuta, M. Ishii, Y. Sugimoto, M. Nakao, T. Yokomizo. Expression of leukotriene B4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation. Cell Mol Immunol (2020) (doi:10.1038/s41423-020-00559-7)

16. Kaji S., T. Irino, M. Kusuhara, R. Makuuchi, Y. Yamakawa, M. Tokunaga, Y. Tanizawa, E. Bando, T. Kawamura, K. Kami, Y. Ohashi, S. Zhang, H. Orita, H.C. Lee-Okada, T. Fukunaga, M. Terashima. Metabolomic profiling of gastric cancer tissues identified potential biomarkers for predicting peritoneal recurrence. Gastric Cancer 23, 874-883 (2020) (doi:10.1007/s10120-020-01065-5)

17. Jimbo K., T. Okuno, R. Ohgaki, K. Nishikubo, Y. Kitamura, Y. Sakurai, L. Quan, H. Shoji, Y. Kanai, T. Shimizu, T. Yokomizo. A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. PLoS One 15, e0241869 (2020) (doi:10.1371/journal.pone.0241869)

18. Ishizuka K., K. Kon, H.C. Lee-Okada, K. Arai, A. Uchiyama, S. Yamashina, T. Yokomizo, K. Ikejima. Aging exacerbates high-fat diet-induced steatohepatitis through alteration in hepatic lipid metabolism in mice. J. Gastroenterol. Hepatol. 35, 1437-1448 (2020) (doi:10.1111/jgh.15006)

19. Ishimine M., T. Yokomizo, H.C. Lee-Okada. Carboxylesterase 2: A Key Enzyme in Drug and Prodrug Metabolism. Juntendo Med J 66, 120-124 (2020)

20. Ishihara E., Y. Nagaoka, T. Okuno, S. Kofuji, M. Ishigami-Yuasa, H. Kagechika, K. Kamimura, S. Terai, T. Yokomizo, Y. Sugimoto, Y. Fujita, A. Suzuki, H. Nishina. Prostaglandin E2 and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition. Genes Cells 25, 197-214 (2020) (doi:10.1111/gtc.12750)

21. Hosooka T., Y. Hosokawa, K. Matsugi, M. Shinohara, Y. Senga, Y. Tamori, C. Aoki, S. Matsui, T. Sasaki, T. Kitamura, M. Kuroda, H. Sakaue, K. Nomura, K. Yoshino, Y. Nabatame, Y. Itoh, K. Yamaguchi, Y. Hayashi, J. Nakae, D. Accili, T. Yokomizo, S. Seino, M. Kasuga, W. Ogawa. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis. Proc. Natl. Acad. Sci. U. S. A. 117, 11674-11684 (2020) (doi:10.1073/pnas.1921015117)

22. Horii Y., M. Nakaya, H. Ohara, H. Nishihara, K. Watari, A. Nagasaka, T. Nakaya, Y. Sugiura, T. Okuno, T. Koga, A. Tanaka, T. Yokomizo, H. Kurose. Leukotriene B4 receptor 1 exacerbates inflammation following myocardial infarction. FASEB J. 34, 8749-8763 (2020) (doi:10.1096/fj.202000041R)

23. Hirakata T., A. Matsuda, T. Yokomizo. Leukotriene B4 receptors as therapeutic targets for ophthalmic diseases. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1865, 158756 (2020) (doi:10.1016/j.bbalip.2020.158756)

24. Han B., H.C. Lee-Okada, M. Ishimine, H. Orita, K. Nishikawa, T. Takagaki, K. Kajino, T. Yokomizo, O. Hino, T. Kobayashi. Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells. FEBS Open Bio 10, 2375-2387 (2020) (doi:10.1002/2211-5463.12985)

25. Fujihira H., Y. Masahara-Negishi, Y. Akimoto, H. Hirayama, H.C. Lee, B.A. Story, W.F. Mueller, P. Jakob, S. Clauder-Munster, L.M. Steinmetz, S.K. Radhakrishnan, H. Kawakami, Y. Kamada, E. Miyoshi, T. Yokomizo, T. Suzuki. Liver-specific deletion of Ngly1 causes abnormal nuclear morphology and lipid metabolism under food stress. Biochim Biophys Acta Mol Basis Dis 1866, 165588 (2020) (doi:10.1016/j.bbadis.2019.165588)

26. Zhang S., Y. Kohira, S. Oerita, M. Ishimine, T. Kobayashi, S.M.B. Chua, H. Nakaoka, I. Inoue, O. Hino, T. Yokomizo, T. Fukunaga, L.-O. H.C. Sensitization of Gastric Cancer Cells to Irinotecan by p53 Activation. BPB Rep. 2, 130-133 (2019)
27. Tamada K., S. Nakajima, N. Ogawa, M. Inada, H. Shibasaki, A. Sato, R. Takasawa, A. Yoshimori, Y. Suzuki, N. Watanabe, T. Oyama, H. Abe, S. Inoue, T. Abe, T. Yokomizo, S. Tanuma. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses. Biochem. Biophys. Res. Commun. 511, 665-670 (2019) (doi:10.1016/j.bbrc.2019.01.136)

28. Sasaki F., T. Yokomizo. The leukotriene receptors as therapeutic targets of inflammatory diseases. Int. Immunol. 31, 607-615 (2019) (doi:10.1093/intimm/dxz044)

29. Saito T., A. Kuma, Y. Sugiura, Y. Ichimura, M. Obata, H. Kitamura, S. Okuda, H.C. Lee, K. Ikeda, Y. Kanegae, I. Saito, J. Auwerx, H. Motohashi, M. Suematsu, T. Soga, T. Yokomizo, S. Waguri, N. Mizushima, M. Komatsu. Autophagy regulates lipid metabolism through selective turnover of NCoR1. Nat Commun 10, 1567 (2019) (doi:10.1038/s41467-019-08829-3)

30. Okuno T., S. Koutsogiannaki, L. Hou, W. Bu, U. Ohto, R.G. Eckenhoff, T. Yokomizo, K. Yuki. Volatile anesthetics isoflurane and sevoflurane directly target and attenuate Toll-like receptor 4 system. FASEB J. 33, 14528-14541 (2019) (doi:10.1096/fj.201901570R)

31. Nagatake T., S.I. Hirata, T. Koga, E. Kuroda, S. Kobari, H. Suzuki, K. Hosomi, N. Matsumoto, Y. Yanrismet, M. Shimojou, S. Morimoto, F. Sasaki, K.J. Ishii, T. Yokomizo, J. Kunisawa. BLT1 mediates commensal bacteria-dependent innate immune signals to enhance antigen-specific intestinal IgA responses. Mucosal Immunol 12, 1082-1091 (2019) (doi:10.1038/s41385-019-0175-z)

32. Matsuda A., Y. Asada, N. Suita, S. Iwamoto, T. Hirakata, N. Yokoi, Y. Ohkawa, Y. Okada, T. Yokomizo, N. Ebihara. Transcriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing. J. Allergy Clin. Immunol. 143, 1610-1614 e1616 (2019) (doi:10.1016/j.jaci.2018.11.007)

33. Maruyama N., T. Takai, S. Kamijo, P. Suchiva, M. Ohba, T. Takeshige, M. Suzuki, M. Hara, K. Matsuno, S. Harada, N. Harada, S. Nakae, K. Sudo, T. Okuno, T. Yokomizo, H. Ogawa, K. Okumura, S. Ikeda. Cyclooxygenase inhibition in mice heightens adaptive- and innate-type responses against inhaled protease allergen and IL-33. Allergy 74, 2237-2240 (2019) (doi:10.1111/all.13831)

34. Lee H.C., M. Tominaga, K. Yasukawa, M. Ohba, N. Takahashi, K. Honda, T. Okuno, K. Takamori, T. Yokomizo. Dietary supplementation of omega-3 fatty acid eicosapentaenoic acid does not ameliorate pruritus in murine models of atopic dermatitis and psoriasis. J. Dermatol. Sci. 95, 130-133 (2019) (doi:10.1016/j.jdermsci.2019.07.010)

35. Koutsogiannaki S., L. Hou, H. Babazada, T. Okuno, N. Blazon-Brown, S.G. Soriano, T. Yokomizo, K. Yuki. The volatile anesthetic sevoflurane reduces neutrophil apoptosis via Fas death domain-Fas-associated death domain interaction. FASEB J. 33, 12668-12679 (2019) (doi:10.1096/fj.201901360R)

36. Kamata M., H. Amano, Y. Ito, T. Fujita, F. Otaka, K. Hosono, K. Kamata, Y. Takeuchi, T. Yokomizo, T. Shimizu, M. Majima. Correction: Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. PLoS One 14, e0215625 (2019) (doi:10.1371/journal.pone.0215625)

37. Kamata M., H. Amano, Y. Ito, T. Fujita, F. Otaka, K. Hosono, K. Kamata, Y. Takeuchi, T. Yokomizo, T. Shimizu, M. Majima. Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. PLoS One 14, e0202842 (2019) (doi:10.1371/journal.pone.0202842)

38. Jo-Watanabe A., T. Okuno, T. Yokomizo. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. Int J Mol Sci 20, 3580 (2019) (doi:10.3390/ijms20143580)

39. Jagusch H., M. Werner, T. Okuno, T. Yokomizo, O. Werz, G. Pohnert. An Alternative Pathway to Leukotriene B4 Enantiomers Involving a 1,8-Diol-Forming Reaction of an Algal Oxylipin. Org Lett 21, 4667-4670 (2019) (doi:10.1021/acs.orglett.9b01554)

40. Hirakata T., T. Yokomizo, A. Matsuda. The roles of omega-3 fatty acids and resolvins in allergic conjunctivitis. Curr Opin Allergy Clin Immunol 19, 517-525 (2019) (doi:10.1097/ACI.0000000000000561)

41. Hirakata T., H.C. Lee, M. Ohba, K. Saeki, T. Okuno, A. Murakami, A. Matsuda, T. Yokomizo. Dietary omega-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. FASEB J. 33, 3392-3403 (2019) (doi:10.1096/fj.201801805R)

42. Yokomizo T., M. Nakamura, T. Shimizu. Leukotriene receptors as potential therapeutic targets. J. Clin. Invest. 128, 2691-2701 (2018) (doi:10.1172/JCI97946)

43. Shoji H., N. Ikeda, T. Kitamura, H. Suganuma, M. Ohba, T. Okuno, T. Yokomizo, T. Shimizu. Urinary prostaglandin D2 metabolite excretion during the first six months of life was significantly lower in breast-fed than formula-fed infants. Acta Paediatr. 107, 95-100 (2018) (doi:10.1111/apa.14068)

44. Sasaki F., T. Koga, M. Ohba, K. Saeki, T. Okuno, K. Ishikawa, T. Nakama, S. Nakao, S. Yoshida, T. Ishibashi, H. Ahmadieh, M.R. Kanavi, A. Hafezi-Moghadam, J.M. Penninger, K.H. Sonoda, T. Yokomizo. Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models. JCI Insight 3, 96902 (2018) (doi:10.1172/jci.insight.96902)

45. Okuno T., T. Yokomizo. Biological functions of 12(S)-hydroxyheptadecatrienoic acid as a ligand of leukotriene B4 receptor 2. Inflamm Regen 38, 29 (2018) (doi:10.1186/s41232-018-0087-4)

46. Okuno T., M.A. Gijon, S. Zarini, S.A. Martin, R.M. Barkley, C.A. Johnson, M. Ohba, T. Yokomizo, R.C. Murphy. Altered eicosanoid production and phospholipid remodeling during cell culture. J. Lipid Res. 59, 542-549 (2018) (doi:10.1194/jlr.M083030)

47. Ohba M., K. Saeki, T. Koga, T. Okuno, Y. Kobayashi, T. Yokomizo. Profiling of bioactive lipids in different dendritic cell subsets using an improved multiplex quantitative LC-MS/MS method. Biochem. Biophys. Res. Commun. 504, 562-568 (2018) (doi:10.1016/j.bbrc.2018.06.026)

48. Nakanishi Y., M. Tan, T. Ichiki, A. Inoue, J.I. Yoshihara, N. Maekawa, I. Takenoshita, K. Yanagida, S. Yamahira, S. Yamaguchi, J. Aoki, T. Nagamune, T. Yokomizo, T. Shimizu, M. Nakamura. Stepwise phosphorylation of leukotriene B4 receptor 1 defines cellular responses to leukotriene B4. Sci Signal 11, (2018) (doi:10.1126/scisignal.aao5390)

49. Liu M., J. Shen, H. Yuan, F. Chen, H. Song, H. Qin, Y. Li, J. Xu, Q. Ye, S. Li, K. Saeki, T. Yokomizo. Leukotriene B4 receptor 2 regulates the proliferation, migration, and barrier integrity of bronchial epithelial cells. J. Cell. Physiol. 233, 6117-6124 (2018) (doi:10.1002/jcp.26455)

50. Lee H.C., T. Yokomizo. Applications of mass spectrometry-based targeted and non-targeted lipidomics. Biochem. Biophys. Res. Commun. 504, 576-581 (2018) (doi:10.1016/j.bbrc.2018.03.081)

51. Kawanishi N., K. Takagi, H.C. Lee, D. Nakano, T. Okuno, T. Yokomizo, S. Machida. Endurance exercise training and high-fat diet differentially affect composition of diacylglycerol molecular species in rat skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 314, R892-R901 (2018) (doi:10.1152/ajpregu.00371.2017)

52. Ishimine M., H.C. Lee, H. Nakaoka, H. Orita, T. Kobayashi, K. Mizuguchi, M. Endo, I. Inoue, K. Sato, T. Yokomizo. The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer. Dis. Markers 2018, 5280736 (2018) (doi:10.1155/2018/5280736)

53. Hori T., T. Okuno, K. Hirata, K. Yamashita, Y. Kawano, M. Yamamoto, M. Hato, M. Nakamura, T. Shimizu, T. Yokomizo, M. Miyano, S. Yokoyama. Na(+)-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. Nat. Chem. Biol. 14, 262-269 (2018) (doi:10.1038/nchembio.2547)

54. Takeda T., Y. Komiya, T. Koga, T. Ishida, Y. Ishii, Y. Kikuta, M. Nakaya, H. Kurose, T. Yokomizo, T. Shimizu, H. Uchi, M. Furue, H. Yamada. Dioxin-induced increase in leukotriene B4 biosynthesis through the aryl hydrocarbon receptor and its relevance to hepatotoxicity owing to neutrophil infiltration. J. Biol. Chem. 292, 10586-10599 (2017) (doi:10.1074/jbc.M116.764332)

55. Sasaki F., T. Koga, K. Saeki, T. Okuno, S. Kazuno, T. Fujimura, Y. Ohkawa, T. Yokomizo. Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1. PLoS One 12, e0185133 (2017) (doi:10.1371/journal.pone.0185133)

56. Saeki K., T. Yokomizo. Identification, signaling, and functions of LTB4 receptors. Semin. Immunol. 33, 30-36 (2017) (doi:10.1016/j.smim.2017.07.010)

57. Okuno T., S. Koutsogiannaki, M. Ohba, M. Chamberlain, W. Bu, F.Y. Lin, R.G. Eckenhoff, T. Yokomizo, K. Yuki. Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production. FASEB J. 31, 1584-1594 (2017) (doi:10.1096/fj.201601095R)

58. Luo L., R. Tanaka, S. Kanazawa, F. Lu, A. Hayashi, T. Yokomizo, H. Mizuno. A synthetic leukotriene B4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J. Diabetes Complications 31, 13-20 (2017) (doi:10.1016/j.jdiacomp.2016.09.002)

59. Koutsogiannaki S., M.M. Schaefers, T. Okuno, M. Ohba, T. Yokomizo, G.P. Priebe, J.A. DiNardo, S.G. Sulpicio, K. Yuki. From the Cover: Prolonged Exposure to Volatile Anesthetic Isoflurane Worsens the Outcome of Polymicrobial Abdominal Sepsis. Toxicol. Sci. 156, 402-411 (2017) (doi:10.1093/toxsci/kfw261)

60. Iwamoto S., T. Koga, M. Ohba, T. Okuno, M. Koike, A. Murakami, A. Matsuda, T. Yokomizo. Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2. Sci Rep 7, 13267 (2017) (doi:10.1038/s41598-017-13122-8)

61. Ikeda K., T. Koga, F. Sasaki, A. Ueno, K. Saeki, T. Okuno, T. Yokomizo. Generation and characterization of a human-mouse chimeric high-affinity antibody that detects the DYKDDDDK FLAG peptide. Biochem. Biophys. Res. Commun. 486, 1077-1082 (2017) (doi:10.1016/j.bbrc.2017.03.165)

62. Hijioka M., J. Anan, H. Ishibashi, Y. Kurauchi, A. Hisatsune, T. Seki, T. Koga, T. Yokomizo, T. Shimizu, H. Katsuki. Inhibition of Leukotriene B4 Action Mitigates Intracerebral Hemorrhage-Associated Pathological Events in Mice. J. Pharmacol. Exp. Ther. 360, 399-408 (2017) (doi:10.1124/jpet.116.238824)

63. Tabe Y., Y. Hatanaka, M. Nakashiro, K. Sekihara, S. Yamamoto, H. Matsushita, S. Kazuno, T. Fujimura, T. Ikegami, K. Nakanaga, H. Matsumoto, T. Ueno, J. Aoki, T. Yokomizo, M. Konopleva, M. Andreeff, T. Miida, K. Iwabuchi, K. Sasai. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells. Int. J. Radiat. Biol. 92, 24-34 (2016) (doi:10.3109/09553002.2015.1106021)

64. Shigematsu M., T. Koga, A. Ishimori, K. Saeki, Y. Ishii, Y. Taketomi, M. Ohba, A. Jo-Watanabe, T. Okuno, N. Harada, T. Harayama, H. Shindou, J.D. Li, M. Murakami, S. Hoka, T. Yokomizo. Leukotriene B4 receptor type 2 protects against pneumolysin-dependent acute lung injury. Sci Rep 6, 34560 (2016) (doi:10.1038/srep34560)

65. Oba J., T. Nakahara, A. Hashimoto-Hachiya, M. Liu, T. Abe, A. Hagihara, T. Yokomizo, M. Furue. CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis. PLoS One 11, e0149285 (2016) (doi:10.1371/journal.pone.0149285)

66. Kojo K., Y. Ito, K. Eshima, N. Nishizawa, H. Ohkubo, T. Yokomizo, T. Shimizu, M. Watanabe, M. Majima. BLT1 signalling protects the liver against acetaminophen hepatotoxicity by preventing excessive accumulation of hepatic neutrophils. Sci Rep 6, 29650 (2016) (doi:10.1038/srep29650)

67. Ishii Y., K. Saeki, M. Liu, F. Sasaki, T. Koga, K. Kitajima, C. Meno, T. Okuno, T. Yokomizo. Leukotriene B4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins. FASEB J. 30, 933-947 (2016) (doi:10.1096/fj.15-279653)

68. Ichiki T., T. Koga, T. Yokomizo. Receptor for Advanced Glycation End Products Regulates Leukotriene B4 Receptor 1 Signaling. DNA Cell Biol. 35, 747-750 (2016) (doi:10.1089/dna.2016.3552)

69. Ichiki T., T. Koga, T. Okuno, K. Saeki, Y. Yamamoto, H. Yamamoto, M. Sakaguchi, T. Yokomizo. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J. 30, 1811-1822 (2016) (doi:10.1096/fj.201500117)

70. Chiba T., T. Nakahara, A. Hashimoto-Hachiya, T. Yokomizo, H. Uchi, M. Furue. The leukotriene B4 receptor BLT2 protects barrier function via actin polymerization with phosphorylation of myosin phosphatase target subunit 1 in human keratinocytes. Exp. Dermatol. 25, 532-536 (2016) (doi:10.1111/exd.12976)

71. Zandi S., S. Nakao, K.H. Chun, P. Fiorina, D. Sun, R. Arita, M. Zhao, E. Kim, O. Schueller, S. Campbell, M. Taher, M.I. Melhorn, A. Schering, F. Gatti, S. Tezza, F. Xie, A. Vergani, S. Yoshida, K. Ishikawa, M. Yamaguchi, F. Sasaki, R. Schmidt-Ullrich, Y. Hata, H. Enaida, M. Yuzawa, T. Yokomizo, Y.B. Kim, P. Sweetnam, T. Ishibashi, A. Hafezi-Moghadam. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell reports 10, 1173-1186 (2015) (doi:10.1016/j.celrep.2015.01.050)

72. Yokomizo T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J. Biochem. (Tokyo). 157, 65-71 (2015) (doi:10.1093/jb/mvu078)

73. Sawada Y., T. Honda, S. Hanakawa, S. Nakamizo, T. Murata, Y. Ueharaguchi-Tanada, S. Ono, W. Amano, S. Nakajima, G. Egawa, H. Tanizaki, A. Otsuka, A. Kitoh, T. Dainichi, N. Ogawa, Y. Kobayashi, T. Yokomizo, M. Arita, M. Nakamura, Y. Miyachi, K. Kabashima. Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses. J. Exp. Med. 212, 1921-1930 (2015) (doi:10.1084/jem.20150381)

74. Okuno T., T. Ishitani, T. Yokomizo. Biochemical characterization of three BLT receptors in zebrafish. PLoS One 10, e0117888 (2015) (doi:10.1371/journal.pone.0117888)

75. Liu M., T. Yokomizo. The role of leukotrienes in allergic diseases. Allergol Int 64, 17-26 (2015) (doi:10.1016/j.alit.2014.09.001)

76. Kubota S., M. Watanabe, M. Shirato, T. Okuno, I. Higashimoto, K. Machida, T. Yokomizo, H. Inoue. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice. Eur. J. Pharmacol. 768, 41-48 (2015) (doi:10.1016/j.ejphar.2015.10.013)

77. Hori T., M. Nakamura, T. Yokomizo, T. Shimizu, M. Miyano. The leukotriene B4 receptor BLT1 is stabilized by transmembrane helix capping mutations. Biochem Biophys Rep 4, 243-249 (2015) (doi:10.1016/j.bbrep.2015.09.007)

78. Asahara M., N. Ito, T. Yokomizo, M. Nakamura, T. Shimizu, Y. Yamada. The absence of the leukotriene B4 receptor BLT1 attenuates peripheral inflammation and spinal nociceptive processing following intraplantar formalin injury. Mol Pain 11, 11 (2015) (doi:10.1186/s12990-015-0010-9)

79. Yokomizo T. Aspirin delays skin wound healing. Juntendo Medical Journal 60, 284-286 (2014)
80. Sato Y., H. Hara, T. Okuno, N. Ozaki, S. Suzuki, T. Yokomizo, T. Kaisho, H. Yoshida. IL-27 affects helper T cell responses via regulation of PGE2 production by macrophages. Biochem. Biophys. Res. Commun. 451, 215-221 (2014) (doi:10.1016/j.bbrc.2014.07.096)

81. Obinata H., S. Gutkind, J. Stitham, T. Okuno, T. Yokomizo, J. Hwa, T. Hla. Individual variation of human S1P(1) coding sequence leads to heterogeneity in receptor function and drug interactions. J. Lipid Res. 55, 2665-2675 (2014) (doi:10.1194/jlr.P054163)

82. Liu M., K. Saeki, T. Matsunobu, T. Okuno, T. Koga, Y. Sugimoto, C. Yokoyama, S. Nakamizo, K. Kabashima, S. Narumiya, T. Shimizu, T. Yokomizo. 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J. Exp. Med. 211, 1063-1078 (2014) (doi:10.1084/jem.20132063)

83. Dugu L., T. Nakahara, Z. Wu, H. Uchi, M. Liu, K. Hirano, T. Yokomizo, M. Furue. Neuronatin is related to keratinocyte differentiation by up-regulating involucrin. J. Dermatol. Sci. 73, 225-231 (2014) (doi:10.1016/j.jdermsci.2013.10.008)

84. Back M., W.S. Powell, S.E. Dahlen, J.M. Drazen, J.F. Evans, C.N. Serhan, T. Shimizu, T. Yokomizo, G.E. Rovati. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol. 171, 3551-3574 (2014) (doi:10.1111/bph.12665)

85. Tojo T., Q. Wang, T. Okuno, T. Yokomizo, Y. Kobayashi. Synthesis of (S,5Z,8E,10E)-12-Hydroxyheptadeca-5,8,10-trienoic Acid (12S-HHT) and its Analogues. Synlett 24, 1545-1548 (2013) (doi:10.1055/s-0033-1338961)

86. Taketomi Y., N. Ueno, T. Kojima, H. Sato, R. Murase, K. Yamamoto, S. Tanaka, M. Sakanaka, M. Nakamura, Y. Nishito, M. Kawana, N. Kambe, K. Ikeda, R. Taguchi, S. Nakamizo, K. Kabashima, M.H. Gelb, M. Arita, T. Yokomizo, M. Nakamura, K. Watanabe, H. Hirai, M. Nakamura, Y. Okayama, C. Ra, K. Aritake, Y. Urade, K. Morimoto, Y. Sugimoto, T. Shimizu, S. Narumiya, S. Hara, M. Murakami. Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol 14, 554-563 (2013) (doi:10.1038/ni.2586)

87. Saiwai H., H. Kumamaru, Y. Ohkawa, K. Kubota, K. Kobayakawa, H. Yamada, T. Yokomizo, Y. Iwamoto, S. Okada. Ly6C+ Ly6G- Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J. Neurochem. 125, 74-88 (2013) (doi:10.1111/jnc.12135)

88. Ohkubo H., Y. Ito, T. Minamino, T. Mishima, M. Hirata, K. Hosono, M. Shibuya, T. Yokomizo, T. Shimizu, M. Watanabe, M. Majima. Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. FASEB J. 27, 3132-3143 (2013) (doi:10.1096/fj.13-227421)

89. Matsunobu T., T. Okuno, C. Yokoyama, T. Yokomizo. Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand. J. Lipid Res. 54, 2979-2987 (2013) (doi:10.1194/jlr.M037754)

90. Matsunaga Y., S. Fukuyama, T. Okuno, F. Sasaki, T. Matsunobu, Y. Asai, K. Matsumoto, K. Saeki, M. Oike, Y. Sadamura, K. Machida, Y. Nakanishi, M. Kubo, T. Yokomizo, H. Inoue. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J. 27, 3306-3314 (2013) (doi:10.1096/fj.12-217000)

91. Kan-o K., Y. Matsunaga, S. Fukuyama, A. Moriwaki, H. Hirai-Kitajima, T. Yokomizo, K. Aritake, Y. Urade, Y. Nakanishi, H. Inoue, K. Matsumoto. Mast cells contribute to double-stranded RNA-induced augmentation of airway eosinophilia in a murine model of asthma. Respir. Res. 14, 28 (2013) (doi:10.1186/1465-9921-14-28)

92. Yokota Y., H. Inoue, Y. Matsumura, H. Nabeta, M. Narusawa, A. Watanabe, C. Sakamoto, Y. Hijikata, M. Iga-Murahashi, K. Takayama, F. Sasaki, Y. Nakanishi, T. Yokomizo, K. Tani. Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems. Blood 120, 3444-3454 (2012) (doi:10.1182/blood-2011-10-383240)

93. Sasaki F., T. Okuno, K. Saeki, L. Min, N. Onohara, H. Kato, T. Shimizu, T. Yokomizo. A high-affinity monoclonal antibody against the FLAG tag useful for G-protein-coupled receptor study. Anal. Biochem. 425, 157-165 (2012) (doi:10.1016/j.ab.2012.03.014)

94. Aratake Y., T. Okuno, T. Matsunobu, K. Saeki, R. Takayanagi, S. Furuya, T. Yokomizo. Helix 8 of leukotriene B4 receptor 1 inhibits ligand-induced internalization. FASEB J. 26, 4068-4078 (2012) (doi:10.1096/fj.12-212050)

95. Okuno T., T. Yokomizo. What is the natural ligand of GPR55? J. Biochem. (Tokyo). 149, 495-497 (2011) (doi:10.1093/jb/mvr022)

96. Nakamura M., T. Shimizu. Leukotriene receptors. Chem. Rev. 111, 6231-6298 (2011) (doi:10.1021/cr100392s)

97. Back M., S.E. Dahlen, J.M. Drazen, J.F. Evans, C.N. Serhan, T. Shimizu, T. Yokomizo, G.E. Rovati. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev. 63, 539-584 (2011) (doi:10.1124/pr.110.004184)

98. Xie L., Y. Moroi, G. Tsuji, M. Liu, S. Hayashida, M. Takahara, S. Fukagawa, S. Takeuchi, B. Shan, T. Nakahara, H. Uchi, T. Yokomizo, M. Furue. CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1alpha-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment. Cancer Sci. 101, 2570-2578 (2010) (doi:10.1111/j.1349-7006.2010.01735.x)

99. Toda A., K. Terawaki, S. Yamazaki, K. Saeki, T. Shimizu, T. Yokomizo. Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1. Biochimie 92, 682-691 (2010) (doi:10.1016/j.biochi.2009.12.002)

100. Takekoshi T., Y. Tada, T. Watanabe, M. Sugaya, T. Hoashi, M. Komine, T. Kawashima, T. Shimizu, C.S. Hau, A. Asahina, T. Yokomizo, S. Sato, K. Tamaki. Identification of a novel marker for dendritic cell maturation, mouse transmembrane protein 123. J. Biol. Chem. 285, 31876-31884 (2010) (doi:10.1074/jbc.M110.118877)

101. Saiwai H., Y. Ohkawa, H. Yamada, H. Kumamaru, A. Harada, H. Okano, T. Yokomizo, Y. Iwamoto, S. Okada. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am. J. Pathol. 176, 2352-2366 (2010) (doi:10.2353/ajpath.2010.090839)

102. Okamoto F., K. Saeki, H. Sumimoto, S. Yamasaki, T. Yokomizo. Leukotriene B4 augments and restores Fc gammaRs-dependent phagocytosis in macrophages. J. Biol. Chem. 285, 41113-41121 (2010) (doi:10.1074/jbc.M110.175497)

103. Kihara Y., T. Yokomizo, A. Kunita, Y. Morishita, M. Fukayama, S. Ishii, T. Shimizu. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 394, 673-678 (2010) (doi:10.1016/j.bbrc.2010.03.049)

104. Iizuka Y., T. Okuno, K. Saeki, H. Uozaki, S. Okada, T. Misaka, T. Sato, H. Toh, M. Fukayama, N. Takeda, Y. Kita, T. Shimizu, M. Nakamura, T. Yokomizo. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J. 24, 4678-4690 (2010) (doi:10.1096/fj.10-165050)

105. Hori T., Y. Sato, N. Takahashi, K. Takio, T. Yokomizo, M. Nakamura, T. Shimizu, M. Miyano. Expression, purification and characterization of leukotriene B(4) receptor, BLT1 in Pichia pastoris. Protein Expr. Purif. 72, 66-74 (2010) (doi:10.1016/j.pep.2010.02.013)

106. Yasuda D., T. Okuno, T. Yokomizo, T. Hori, N. Hirota, T. Hashidate, M. Miyano, T. Shimizu, M. Nakamura. Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum. FASEB J. 23, 1470-1481 (2009) (doi:10.1096/fj.08-125385)

107. Murakami N., T. Hashidate, T. Harayama, T. Yokomizo, T. Shimizu, M. Nakamura. Transcriptional regulation of human G2A in monocytes/ macrophages: involvement of c/EBPs, Runx and Pu.1. Genes Cells 14, 1441-1455 (2009) (doi:10.1111/j.1365-2443.2009.01360.x)

108. Irukayama-Tomobe Y., H. Tanaka, T. Yokomizo, T. Hashidate-Yoshida, M. Yanagisawa, T. Sakurai. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc. Natl. Acad. Sci. U. S. A. 106, 3930-3934 (2009) (doi:10.1073/pnas.0811844106)

109. Hikiji H., S. Ishii, T. Yokomizo, T. Takato, T. Shimizu. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc. Natl. Acad. Sci. U. S. A. 106, 21294-21299 (2009) (doi:10.1073/pnas.0905209106)

110. Okuno T., Y. Iizuka, H. Okazaki, T. Yokomizo, R. Taguchi, T. Shimizu. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J. Exp. Med. 205, 759-766 (2008) (doi:10.1084/jem.20072329)

111. Kuramoto M., Y. Sakata, K. Terai, I. Kawasaki, J. Kunitomo, T. Ohishi, T. Yokomizo, S. Takeda, S. Tanaka, Y. Ohishi. Preparation of leukotriene B(4) inhibitory active 2- and 3-(2-aminothiazol-4-yl)benzo[b]furan derivatives and their growth inhibitory activity on human pancreatic cancer cells. Org. Biomol. Chem. 6, 2772-2781 (2008) (doi:10.1039/b803313g)

112. Ito S., Y. Ito, H. Katagiri, T. Suzuki, S. Hoka, T. Yokomizo, T. Shimizu, M. Majima. Leukotriene B4/leukotriene B4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin. Shock 30, 87-91 (2008) (doi:10.1097/shk.0b013e31815d06a1)

113. Hennig R., T. Osman, I. Esposito, N. Giese, S.M. Rao, X.Z. Ding, W.G. Tong, M.W. Buchler, T. Yokomizo, H. Friess, T.E. Adrian. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br. J. Cancer 99, 1064-1073 (2008) (doi:10.1038/sj.bjc.6604655)

114. Hase M., T. Yokomizo, T. Shimizu, M. Nakamura. Characterization of an orphan G protein-coupled receptor, GPR20, that constitutively activates Gi proteins. J. Biol. Chem. 283, 12747-12755 (2008) (doi:10.1074/jbc.M709487200)

115. Ando K., Y. Kawamura, Y. Akai, J. Kunitomo, T. Yokomizo, M. Yamashita, S. Ohta, T. Ohishi, Y. Ohishi. Preparation of 2-, 3-, 4- and 7-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans and their BLT1 and/or BLT2 inhibitory activities. Org. Biomol. Chem. 6, 296-307 (2008) (doi:10.1039/b710935k)

116. Sakata Y., M. Kuramoto, K. Ando, M. Yamaguchi, I. Kawasaki, J. Kunitomo, T. Yokomizo, Y. Ohishi. Preparation of 3-(4-chlorophenyl)-2-(2-aminothiazol-4-yl)-5-methoxybenzo[b]furan derivatives and their leukotriene B(4) inhibitory activity. Org. Biomol. Chem. 5, 3083-3086 (2007) (doi:10.1039/b711391a)

117. Kuniyeda K., T. Okuno, K. Terawaki, M. Miyano, T. Yokomizo, T. Shimizu. Identification of the intracellular region of the leukotriene B4 receptor type 1 that is specifically involved in Gi activation. J. Biol. Chem. 282, 3998-4006 (2007) (doi:10.1074/jbc.M610540200)

118. Ando K., Y. Akai, J. Kunitomo, T. Yokomizo, H. Nakajima, T. Takeuchi, M. Yamashita, S. Ohta, T. Ohishi, Y. Ohishi. Synthesis and biological activities of novel furo[2,3,4-jk][2]benzazepin-4(3H)-one derivatives. Org. Biomol. Chem. 5, 655-663 (2007) (doi:10.1039/b614510h)

119. Hori T., J. Ishijima, T. Yokomizo, H. Ago, T. Shimizu, M. Miyano. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. J. Biochem. (Tokyo). 140, 457-466 (2006) (doi:10.1093/jb/mvj176)

120. Doi K., K. Okamoto, K. Negishi, Y. Suzuki, A. Nakao, T. Fujita, A. Toda, T. Yokomizo, Y. Kita, Y. Kihara, S. Ishii, T. Shimizu, E. Noiri. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am. J. Pathol. 168, 1413-1424 (2006) (doi:10.2353/ajpath.2006.050634)

121. Chiang N., C.N. Serhan, S.E. Dahlen, J.M. Drazen, D.W. Hay, G.E. Rovati, T. Shimizu, T. Yokomizo, C. Brink. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487 (2006) (doi:10.1124/pr.58.3.4)

122. Terawaki K., T. Yokomizo, T. Nagase, A. Toda, M. Taniguchi, K. Hashizume, T. Yagi, T. Shimizu. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J. Immunol. 175, 4217-4225 (2005) (doi:10.4049/jimmunol.175.7.4217)

123. Okuno T., T. Yokomizo, T. Hori, M. Miyano, T. Shimizu. Leukotriene B4 receptor and the function of its helix 8. J. Biol. Chem. 280, 32049-32052 (2005) (doi:10.1074/jbc.R500007200)

124. Matsubara D., T. Niki, S. Ishikawa, A. Goto, E. Ohara, T. Yokomizo, C.W. Heizmann, H. Aburatani, S. Moriyama, H. Moriyama, Y. Nishimura, N. Funata, M. Fukayama. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 96, 844-857 (2005) (doi:10.1111/j.1349-7006.2005.00121.x)

125. Iizuka Y., T. Yokomizo, K. Terawaki, M. Komine, K. Tamaki, T. Shimizu. Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J. Biol. Chem. 280, 24816-24823 (2005) (doi:10.1074/jbc.M413257200)

126. Ando K., E. Tsuji, Y. Ando, J. Kunitomo, R. Kobayashi, T. Yokomizo, T. Shimizu, M. Yamashita, S. Ohta, T. Nabe, S. Kohno, Y. Ohishi. Synthesis of 2-, 4- and 5-(2-alkylcarbamoyl-1-methylvinyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity. Org. Biomol. Chem. 3, 2129-2139 (2005) (doi:10.1039/b503615a)

127. Murakami N., T. Yokomizo, T. Okuno, T. Shimizu. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J. Biol. Chem. 279, 42484-42491 (2004) (doi:10.1074/jbc.M406561200)

128. Hori T., T. Yokomizo, H. Ago, M. Sugahara, G. Ueno, M. Yamamoto, T. Kumasaka, T. Shimizu, M. Miyano. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-Oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J. Biol. Chem. 279, 22615-22623 (2004) (doi:10.1074/jbc.M312655200)

129. Brink C., S.E. Dahlen, J. Drazen, J.F. Evans, D.W. Hay, G.E. Rovati, C.N. Serhan, T. Shimizu, T. Yokomizo. International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 56, 149-157 (2004) (doi:10.1124/pr.56.1.4)

130. Yamauchi T., J. Kamon, Y. Ito, A. Tsuchida, T. Yokomizo, S. Kita, T. Sugiyama, M. Miyagishi, K. Hara, M. Tsunoda, K. Murakami, T. Ohteki, S. Uchida, S. Takekawa, H. Waki, N.H. Tsuno, Y. Shibata, Y. Terauchi, P. Froguel, K. Tobe, S. Koyasu, K. Taira, T. Kitamura, T. Shimizu, R. Nagai, T. Kadowaki. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003) (doi:10.1038/nature01705)

131. Usui H., M. Taniguchi, T. Yokomizo, T. Shimizu. Plexin-A1 and plexin-B1 specifically interact at their cytoplasmic domains. Biochem. Biophys. Res. Commun. 300, 927-931 (2003) (doi:10.1016/s0006-291x(02)02966-2)

132. Okuno T., H. Ago, K. Terawaki, M. Miyano, T. Shimizu, T. Yokomizo. Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation. J. Biol. Chem. 278, 41500-41509 (2003) (doi:10.1074/jbc.M307335200)

133. Obinata H., T. Yokomizo, T. Shimizu, T. Izumi. Glucocorticoids up-regulate leukotriene B4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem. Biophys. Res. Commun. 309, 114-119 (2003) (doi:10.1016/s0006-291x(03)01554-7)

134. Masuda K., H. Itoh, T. Sakihama, C. Akiyama, K. Takahashi, R. Fukuda, T. Yokomizo, T. Shimizu, T. Kodama, T. Hamakubo. A combinatorial G protein-coupled receptor reconstitution system on budded baculovirus. Evidence for Galpha and Galphao coupling to a human leukotriene B4 receptor. J. Biol. Chem. 278, 24552-24562 (2003) (doi:10.1074/jbc.M302801200)

135. Brink C., S.E. Dahlen, J. Drazen, J.F. Evans, D.W. Hay, S. Nicosia, C.N. Serhan, T. Shimizu, T. Yokomizo. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227 (2003) (doi:10.1124/pr.55.1.8)

136. Yokomizo T., E. Noiri, T. Izumi, T. Shimizu. In vivo chemotaxis using CHO cells expressing human leukotriene B4 receptor. Adv. Exp. Med. Biol. 507, 357-361 (2002) (doi:10.1007/978-1-4615-0193-0_55)

137. Toda A., T. Yokomizo, T. Shimizu. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat. 68-69, 575-585 (2002) (doi:10.1016/s0090-6980(02)00056-4)

138. Ogasawara H., S. Ishii, T. Yokomizo, T. Kakinuma, M. Komine, K. Tamaki, T. Shimizu, T. Izumi. Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. J. Biol. Chem. 277, 18763-18768 (2002) (doi:10.1074/jbc.M109447200)

139. Noiri E., H. Satoh, J. Taguchi, S.V. Brodsky, A. Nakao, Y. Ogawa, S. Nishijima, T. Yokomizo, K. Tokunaga, T. Fujita. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40, 535-540 (2002) (doi:10.1161/01.hyp.0000033974.57407.82)

140. Izumi T., T. Yokomizo, H. Obinata, H. Ogasawara, T. Shimizu. Leukotriene receptors: classification, gene expression, and signal transduction. J. Biochem. (Tokyo). 132, 1-6 (2002) (doi:10.1093/oxfordjournals.jbchem.a003185)

141. Ito N., T. Yokomizo, T. Sasaki, H. Kurosu, J. Penninger, Y. Kanaho, T. Katada, K. Hanaoka, T. Shimizu. Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B4-induced enzyme release. J. Biol. Chem. 277, 44898-44904 (2002) (doi:10.1074/jbc.M208051200)

142. Yokomizo T., K. Kato, H. Hagiya, T. Izumi, T. Shimizu. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J. Biol. Chem. 276, 12454-12459 (2001) (doi:10.1074/jbc.M011361200)

143. Yokomizo T., T. Izumi, T. Shimizu. Co-expression of two LTB4 receptors in human mononuclear cells. Life Sci. 68, 2207-2212 (2001) (doi:10.1016/s0024-3205(01)01007-4)

144. Yokomizo T., T. Izumi, T. Shimizu. Leukotriene B4: metabolism and signal transduction. Arch. Biochem. Biophys. 385, 231-241 (2001) (doi:10.1006/abbi.2000.2168)

145. Yamamoto T., T. Yokomizo, A. Nakao, T. Izumi, T. Shimizu. Immunohistochemical localization of guinea-pig leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase. Eur. J. Biochem. 268, 6105-6113 (2001) (doi:10.1046/j.0014-2956.2001.02462.x)

146. Fukunaga K., S. Ishii, K. Asano, T. Yokomizo, T. Shiomi, T. Shimizu, K. Yamaguchi. Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation. J. Biol. Chem. 276, 43025-43030 (2001) (doi:10.1074/jbc.M108288200)

147. Yokomizo T., K. Masuda, K. Kato, A. Toda, T. Izumi, T. Shimizu. Leukotriene B4 receptor. Cloning and intracellular signaling. Am. J. Respir. Crit. Care Med. 161, S51-55 (2000) (doi:10.1164/ajrccm.161.supplement_1.ltta-11)

148. Yokomizo T., K. Kato, K. Terawaki, T. Izumi, T. Shimizu. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432 (2000) (doi:10.1084/jem.192.3.421)

149. Okamoto H., N. Takuwa, T. Yokomizo, N. Sugimoto, S. Sakurada, H. Shigematsu, Y. Takuwa. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol. Cell. Biol. 20, 9247-9261 (2000) (doi:10.1128/mcb.20.24.9247-9261.2000)

150. Noiri E., T. Yokomizo, A. Nakao, T. Izumi, T. Fujita, S. Kimura, T. Shimizu. An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 97, 823-828 (2000) (doi:10.1073/pnas.97.2.823)

151. Kato K., T. Yokomizo, T. Izumi, T. Shimizu. Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. J. Exp. Med. 192, 413-420 (2000) (doi:10.1084/jem.192.3.413)

152. Toda A., T. Yokomizo, K. Masuda, A. Nakao, T. Izumi, T. Shimizu. Cloning and characterization of rat leukotriene B(4) receptor. Biochem. Biophys. Res. Commun. 262, 806-812 (1999) (doi:10.1006/bbrc.1999.1284)

153. Masuda K., T. Yokomizo, T. Izumi, T. Shimizu. cDNA cloning and characterization of guinea-pig leukotriene B4 receptor. Biochem. J. 342 ( Pt 1), 79-85 (1999)
154. Izumi T., T. Yokomizo, T. Igarashi, T. Shimizu. Molecular cloning and characterization of leukotriene B4 receptor. Adv. Exp. Med. Biol. 469, 237-244 (1999) (doi:10.1007/978-1-4615-4793-8_35)

155. Igarashi T., T. Yokomizo, O. Tsutsumi, Y. Taketani, T. Shimizu, T. Izumi. Characterization of the leukotriene B4 receptor in porcine leukocytes. Separation and reconstitution with heterotrimeric GTP-binding proteins. Eur. J. Biochem. 259, 419-425 (1999) (doi:10.1046/j.1432-1327.1999.00054.x)

156. Hirabayashi T., K. Kume, K. Hirose, T. Yokomizo, M. Iino, H. Itoh, T. Shimizu. Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2. J. Biol. Chem. 274, 5163-5169 (1999) (doi:10.1074/jbc.274.8.5163)

157. Boie Y., R. Stocco, N. Sawyer, G.M. Greig, S. Kargman, D.M. Slipetz, G.P. O'Neill, T. Shimizu, T. Yokomizo, K.M. Metters, M. Abramovitz. Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue. Eur. J. Pharmacol. 380, 203-213 (1999) (doi:10.1016/s0014-2999(99)00514-2)

158. Yokomizo T., Y. Ogawa, N. Uozumi, K. Kume, T. Izumi, T. Shimizu. cDNA cloning and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. Adv. Exp. Med. Biol. 407, 151-156 (1997) (doi:10.1007/978-1-4899-1813-0_23)

159. Yokomizo T., T. Izumi, K. Chang, Y. Takuwa, T. Shimizu. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 (1997) (doi:10.1038/42506)

160. Yokomizo T., Y. Ogawa, N. Uozumi, K. Kume, T. Izumi, T. Shimizu. cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem. 271, 2844-2850 (1996) (doi:10.1074/jbc.271.5.2844)

161. Yokomizo T., N. Uozumi, T. Takahashi, K. Kume, T. Izumi, T. Shimizu. Leukotriene A4 hydrolase and leukotriene B4 metabolism. J. Lipid Mediat. Cell Signal. 12, 321-332 (1995) (doi:10.1016/0929-7855(95)00041-n)

162. Yokomizo T., T. Izumi, T. Takahashi, T. Kasama, Y. Kobayashi, F. Sato, Y. Taketani, T. Shimizu. Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney. Purification and properties of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem. 268, 18128-18135 (1993)

和文
1. 横溝岳彦. ロイコトリエンB4受容体の生理・病態における役割. 生化学 93, 124-136 (2021)
2. 佐々木文之, 横溝岳彦. ロイコトリエンB4第1受容体は滲出型加齢黄斑変性症の新規治療標的となる. 実験医学 37, 411-414 (2019)
3. 横溝岳彦. 【脂質クオリティ 生命機能と健康を支える脂質の多様性】 (第3章)リポクオリティによる疾患制御 ロイコトリエン受容体の生理・病態における役割. 実験医学 36, 1681-1686 (2018)
4. 平形寿彬, 李賢喆, 横溝岳彦. 脂肪酸由来の脂質メディエーターによるアレルギー炎症の制御. 臨床免疫・アレルギー科 70, 209-215 (2018)
5. 岩本怜, 横溝岳彦. 【生理活性脂質研究の最前線】 BLT2受容体の上皮保護作用. 炎症と免疫 26, 380-383 (2018)
6. 古賀友紹, 佐伯和子, 横溝岳彦. 生理活性脂質ロイコトリエンB4とその受容体による免疫調節機構. 臨床免疫・アレルギー科 70, 209-215 (2018)
7. 石井由美子, 劉珉, 佐伯和子, 横溝岳彦. 皮膚保護作用を有する脂質メディエーター12-HHT. 臨床免疫・アレルギー科 67, 106-114 (2017)
8. 横溝岳彦. 「脂質マシナリー」研究 脂質メディエーターの最新の研究成果. 腎臓内科・泌尿器科 4, 610-617 (2016)
9. 横溝岳彦. 快人快説 最先端の研究テクノロジー紹介 微量サンプル中の微量脂質を定量化する驚異の質量分析技術. LiSA 23, 1179-1188 (2016)
10. 横溝岳彦. 【脂質ワールド】 新規脂質メディエーターと受容体 古くて新しい脂質メディエーター・12-ヒドロキシヘプタデカトリエン酸の生理作用. 生体の科学 67, 232-236 (2016)
11. 横溝岳彦, ed. 特集 脂質ワールド. 生体の科学, ed. 横溝岳彦. Vol. 67. 2016, 医学書院: 東京. 76.
12. 市木貴子, 古賀友紹, 横溝岳彦. 【GPCR研究の最前線2016】 GPCR機能の新展開【免疫・炎症】 ロイコトリエン受容体. 医学のあゆみ 256, 554-560 (2016)
13. 横溝岳彦. 【アセトアミノフェン】 薬理学的側面から 古くて新しい謎だらけの薬. LiSA 22, 874-877 (2015)
14. 横溝岳彦. 第1世代脂質メディエーター エイコサノイド. 実験医学 33, 2344-2348 (2015)
15. 李賢哲, 奥野利明, 横溝岳彦. 脂質メディエーターによる免疫・炎症応答の制御. 臨床免疫・アレルギー科 64, 386-390 (2015)
16. 佐伯和子, 劉. 珉, 横溝岳彦. 血小板由来の脂質メディエーター12-HHTは角化細胞の移動を亢進させ皮膚創傷治癒を促進する. 血栓止血 26, 611-618 (2015)
17. 佐伯和子, 劉. 珉, 横溝岳彦. 12-HHT 皮膚創傷治癒に働く新しいCOX代謝物. 医学のあゆみ 254, 1121-1125 (2015)
18. 五十嵐靖之, 清水孝雄, 徳村彰, 西島正弘, 村上誠, 横溝岳彦. あなたの知らない「脂質」の世界 脂質研究の過去、現在、そして未来. 実験医学 33, 2336-2343 (2015)
19. 橫溝岳彦. 生命応答を制御する脂質マシナリー. JSI Newsletter 22, 29 (2014)
20. 横溝岳彦. Scienceに掲載された論文のリトラクションにかかわった話 生データの前では,大教授も学部生も平等なのだ. LiSA 21, 988-989 (2014)
21. 横溝岳彦. アスピリンを服用すると血液が凝固しにくくなるメカニズムとは. LiSA 21, 739-741 (2014)
22. 佐伯和子, 横溝岳彦. ロイコトリエンの生体内における役割. 医学のあゆみ 248, 970-976 (2014)
23. 佐伯和子, 劉珉, 横溝岳彦. アスピリンによる生理活性脂質12-HHTの産生阻害は皮膚創傷治癒の遅延をひきおこす. 実験医学 32, 2267-2270 (2014)
24. 横溝岳彦. 脂質マシナリー Lipid machinery. 感染・炎症・免疫 43, 44-54 (2013)
25. 横溝岳彦. 脂質由来メディエーターの種類・構造と生体での役割. 内分泌・糖尿病・代謝内科 36, 540547 (2013)
26. 横溝岳彦. エイコサノイド:臨床検査項目としての可能性. 臨床化学 42, 221-228 (2013)
27. 奥野利明, 劉珉, 佐伯和子, 松延武彦, 横溝岳彦. 皮膚創傷治癒における新規脂質メディエーター・12-HHTの役割. 順天堂醫事雑誌 59, 528-529 (2013)
28. 古川龍彦, 横溝岳彦, eds. 特集:ストレス応答分子:分子メカニズムの解明と病態の理解. 生化学. Vol. 85. 2013, 日本生化学会: 東京. 133-213.
29. 橫溝岳彦. うちのとくいわざ-生理活性脂質受容体と免疫反応. JSI Newsletter 20, 22 (2012)
30. 横溝岳彦. 腸管粘膜を保護する生理活性脂質12-HHT. The Lipid 23, 295-301 (2012)
31. 横溝岳彦. 【生理活性脂質】 総論 Gタンパク質共役型受容体と生理活性脂質. 臨床検査 56, 117-124 (2012)
32. 佐々木文之, 横溝岳彦. クローズアップ実験法:新規抗FLAG抗体2H8の活用法. 実験医学 30, 2987-2992 (2012)
33. 横溝岳彦. 【慢性炎症と疾患 病態解明と治療の新展開】 新しい治療戦略 脂質メディエーターと炎症制御. 最新医学 65, 2416-2423 (2010)
34. 横溝岳彦, 【免疫疾患】アレルギー病態におけるロイコトリエン, in 臨床免疫学, 山本一彦, Editor. 2010, 日本臨床社: 大阪. p. 47-52.
35. 横溝岳彦. 脂質メディエータと炎症制御. 最新医学 65, 2416-2423 (2010)
36. 横溝岳彦. 【最新G蛋白質共役受容体研究 疾患解明とシグナル制御の新時代】 受容体機能のあらたな展開 脂質メディエータ・炎症・免疫 ロイコトリエン受容体 炎症から免疫へ. 医学のあゆみ 233, 813-818 (2010)
37. 奥野利明, 横溝岳彦. 【分子から個体へと深化する脂質生物学 リピドミクスや脂質イメージングによる局在・機能解析から生体調節系の生理、そして、がん・炎症など疾患の分子機構の理解へ】 脂質メディエーターと受容体 脂質メディエーターは第三世代へ オーファンGPCRの脂質リガンド同定戦略と課題. 実験医学 28, 3373-3377 (2010)
38. 奥野利明, 横溝岳彦. オーファンGPCRの脂質リガンド同定戦略と課題. 実験医学 28, 3373-3377 (2010)
39. 横溝岳彦, 村. 誠, eds. 【情報伝達をつかさどる生理活性物質 脂質メディエーターの機能】 実験医学. Vol. 27. 2009, 羊土社: 東京. 2040-2087.
40. 横溝岳彦, 村上誠. 【情報伝達をつかさどる生理活性物質 脂質メディエーターの機能】 概論 脂質メディエーターの機能 新規創薬への応用をめざす基礎研究. 実験医学 27, 2040-2046 (2009)
41. 横溝岳彦, ed. 【脂質メディエーターと炎症】 炎症と免疫. Vol. 17. 2009: 東京. 357-393.
42. 横溝岳彦. キーワード解説 ロイコトリエン受容体. 日本薬理学雑誌 133, 230-232 (2009)
43. 横溝岳彦. 【情報伝達をつかさどる生理活性物質 脂質メディエーターの機能】 ロイコトリエン受容体の生体内での役割. 実験医学 27, 2053-2058 (2009)
44. 奥野利明, 横溝岳彦. 【脂質メディエーターと炎症】 ロイコトリエンと炎症・免疫. 炎症と免疫 17, 373-378 (2009)
45. 横溝岳彦. 免疫疾患における生理活性脂質受容体の役割. 上原記念生命科学財団研究報告集 22, 1-6 (2008)
46. 横溝岳彦. 1枚の写真館 CHO細胞が走った! 細胞工学 27, 109 (2008)
47. 横溝岳彦. 【脂質の新たな機能を追う】 ロイコトリエンによる免疫制御. 細胞工学 26, 1236-1240 (2007)
48. 横溝岳彦. 【脂質】 脂質関連物質の作用機序 細胞膜受容体の脂質性リガンド エイコサノイド、スフィンゴ脂質と新規抗炎症脂質. 臨床検査 51, 459-468 (2007)
49. 横溝岳彦. 【GPCR研究の新しい流れ】 LTB4受容体の同定とその後の進展. 日本薬理学雑誌 130, 29-33 (2007)
50. 奥野利明, 横溝岳彦. ロイコトリエンB4と呼吸器疾患. 呼吸と循環 55, 423-428 (2007)
51. 横溝岳彦. 脂質因子による免疫反応の制御. 感染・炎症・免疫 36, 196-205 (2006)
52. 横溝岳彦. 生理活性脂質ロイコトリエンB4とその受容体. 福岡医学雑誌 97, 183-191 (2006)
53. 横溝岳彦. 【シグナル受容機構の解明が導く 創薬・治療への躍進】 シグナル受容器の構造と機能 進展する脂質膜受容体研究 最近のトピックス. 実験医学 24, 624-629 (2006)
54. 横溝岳彦. 【臨床免疫学 基礎研究の進歩と最新の臨床】 臨床編 アレルギーの臨床免疫学 アレルギー研究の進歩 免疫疾患・アレルギー病態におけるロイコトリエン. 日本臨床 63, 47-52 (2005)
55. 横溝岳彦. 【ダイナミックに新展開する脂質研究 注目のメタボローム解析などから解明が進むシグナル伝達や疾患・生命現象の本質につながる多彩な機能】 脂質研究の新しいアプローチ オーファン受容体の脂質リガンド探索の戦略. 実験医学 23, 968-976 (2005)
56. 横溝岳彦. 【G蛋白質共役受容体研究の新展開 疾患メカニズムの解析と制御へのあゆみ】 受容体機能の新しい展開 ロイコトリエン受容体 遺伝子欠損マウスの解析と臨床応用へ. 医学のあゆみ 212, 89-94 (2005)
57. 横溝岳彦, 清水孝雄. ケモカインと炎症・再生 ロイコトリエンB4受容体を介した細胞走化性. 炎症・再生 24, 404 (2004)
58. 横溝岳彦. 基礎医学から呼吸器へのメッセージ ロイコトリエンと肺線維症. 分子呼吸器病 8, 511-513 (2004)
59. 寺脇幹, 横溝岳彦. 【ロイコトリエンとアレルギー】 ロイコトリエンと免疫・炎症の基盤. アレルギーの臨床 24, 947-953 (2004)
60. 伊藤伸子, 横溝岳彦. アラキドン酸カスケードに関する最近の知見. ペインクリニック 25, 1050-1058 (2004)
61. 横溝岳彦, 寺脇幹, 清水孝雄. リピッドメディエーターの新展開 ロイコトリエンB4受容体BLT1の生体内での機能. 炎症・再生 23, 397 (2003)
62. 北芳博, 魚住尚紀, 横溝岳彦. 【プロスタグランジン】 生殖生理とプロスタグランジン 着床・妊娠維持. HORMONE FRONTIER IN GYNECOLOGY 10, 281-286 (2003)
63. 横溝岳彦. ロイコトリエンB4の代謝と受容体. 生化学 74, 1139-1147 (2002)
64. 横溝岳彦. 私の博士論文 地図を作る仕事. 蛋白質 核酸 酵素 46, 1414-1415 (2001)
65. 横溝岳彦. 【7回膜貫通型受容体研究の新展開 ポストゲノム時代の受容体研究のゆくえ】 7回膜貫通型受容体分子研究 ロイコトリエン受容体 遺伝子単離から臨床応用へ. 医学のあゆみ 別冊, 50-55 (2001)
66. 寺脇幹, 横溝岳彦. 新しいロイコトリエンB4レセプター. 免疫Immunology Frontier 11, 156-159 (2001)
67. 横溝岳彦. 目でみるバイオサイエンス LTB4受容体の機能と構造. 内科 85, 984-986 (2000)
68. 加藤和彦, 横溝岳彦, 和泉孝志, 清水孝雄. ヒトロイコトリエンB4受容体遺伝子の転写制御. 炎症 20, 437 (2000)
69. 伊藤伸子, 横溝岳彦. 【細胞膜・核内レセプターと脂溶性シグナル分子】 細胞膜レセプターを介する脂溶性シグナル分子の作用機構 脂溶性シグナル分子の細胞膜レセプターとシグナル伝達 ロイコトリエンレセプターとシグナル伝達. 実験医学 18, 174-178 (2000)
70. 横溝岳彦, 石井功. 【新遺伝子工学ハンドブック】 遺伝子の発現解析 遺伝子導入 リポフェクション法. 実験医学 別冊, 126-130 (1999)
71. 横溝岳彦. 【エイコサノイド】 ロイコトリエンB4受容体の構造と機能. 現代医療 31, 185-189 (1999)
72. 横溝岳彦. 【エイコサノイド】 リポキシゲナーゼとリポキシゲナーゼ欠損マウス. 現代医療 31, 95-101 (1999)
73. 横溝岳彦. 【アラキドン酸代謝と血管】 血管における白血球遊走とロイコトリエン. 血管と内皮 9, 55-61 (1999)
74. 山本寿子, 横溝岳彦. 【エイコサノイド】 二つの酵素活性を持つロイコトリエンB4 12水酸基脱水素酵素. 現代医療 31, 116-120 (1999)
75. 増田一之, 横溝岳彦. ロイコトリエンレセプター. 免疫Immunology Frontier 9, 37-41 (1999)
76. 横溝岳彦, 増田一之, 加藤和彦, 和泉孝志, 清水孝雄. プロスタノイドとレセプターの新展開 ロイコトリエンB4受容体の構造と細胞内情報伝達. 生化学 70, 617 (1998)
77. 横溝岳彦, 和泉孝志. ロイコトリエンB4受容体のcDNAクローニング. 呼吸 17, 856-862 (1998)
78. 横溝岳彦. 【脂質メディエーターによる情報伝達 アラキドン酸カスケード研究の新展開】 ロイコトリエンの代謝と受容体 核内受容体にもふれて. 細胞工学 17, 722-729 (1998)
79. 横溝岳彦. インターネットで情報収集 アラキドン酸カスケード研究に関する情報. 細胞工学 17, 682-683 (1998)
80. 和泉孝志, 星野光伸, 横溝岳彦. ロイコトリエン受容体と情報伝達. 炎症 18, 251-258 (1998)
81. 横溝岳彦. ロイコトリエンB4は2つの受容体をもつか? 実験医学 15, 2188-2191 (1997)
82. 横溝岳彦. アラキドン酸カスケード研究の新展開. 実験医学 14, 1580-1583 (1996)
83. 横溝岳彦. 新しいロイコトリエンB4(LTB4)不活性化酵素の精製. 生化学 64, 927 (1992)



研究者 教育活動 ホームページURL